Y
Yan Wei
Researcher at Chinese Academy of Sciences
Publications - 4
Citations - 119
Yan Wei is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Drug delivery & Prodrug. The author has an hindex of 3, co-authored 4 publications receiving 61 citations. Previous affiliations of Yan Wei include Shanghai University.
Papers
More filters
Journal ArticleDOI
Thermosensitive Liposomal Codelivery of HSA-Paclitaxel and HSA-Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer.
TL;DR: With superior tumor accumulation, impressive matrix penetration, and simultaneous action upon tumor cells and PSCs to disrupt PSC-PDA interaction, TSL/HSA-PE treatment combined with heat exhibited strong tumor growth inhibition and apoptosis in vivo.
Journal ArticleDOI
MT1‐MMP‐Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy
Yan Wei,Sha Song,Nianxiu Duan,Feng Wang,Yuxi Wang,Yiwei Yang,Chengyuan Peng,Junjun Li,Di Nie,Xinxin Zhang,Shiyan Guo,Chunliu Zhu,Miaorong Yu,Yong Gan +13 more
TL;DR: The strategy of combining the modulation of tumor vascular promotion with smart nanodrug delivery represents a promising approach to improving drug delivery and therapeutic efficacy in a wide range of hypoperfused tumors.
Journal ArticleDOI
Smart Tumor Microenvironment-Responsive Nanotheranostic Agent for Effective Cancer Therapy
Shiyan Guo,Shiyan Guo,Di Sun,Dalong Ni,Miaorong Yu,Kun Qian,Wei Zhang,Yiwei Yang,Sha Song,Yang Li,Ziyue Xi,Jie Wang,Jingyi Li,Yan Wei,Kaixian Chen,Kaixian Chen,Yong Gan,Zhengtao Wang +17 more
TL;DR: In vivo pharmacodynamics results demonstrate that these synergetic effects caused by CaM‐PB NPs significantly contribute to the inhibition of tumor progression, demonstrating that theCaM‐ PB NPs with sequential theranostic functions are a promising system for effective cancer therapy.
Journal ArticleDOI
Enzyme-Activated Prodrug-Based Smart Liposomes Specifically Enhance Tumor Hemoperfusion with Efficient Drug Delivery to Pancreatic Cancer Cells and Stellate Cells
Nianxiu Duan,Nianxiu Duan,Nianxiu Duan,Junjun Li,Junjun Li,Sha Song,Sha Song,Feng Wang,Yiwei Yang,Di Nie,Caifen Wang,Yingjie Sheng,Yali Tao,Jie Gao,Can Xu,Yan Wei,Yan Wei,Yong Gan +17 more
TL;DR: By enhancing the exposure of DOX and CAL to tumor cells and aPSCs, respectively, in a tumor‐specific manner, MR‐T‐PD exerts superior efficacy without causing additional side effects, and represents a promising paradigm for pancreatic cancer therapy.